Sen F.Demir H.Altun G.D.Özdemir E.Özdemir S.Tosun F.C.2024-06-122024-06-1220202149-6447https://doi.org/10.4274/NTS.GALENOS.2020.0015https://hdl.handle.net/20.500.14551/16803Histologic confirmation of cardiac sarcoidosis (CS) is challenging. When taken into account of either the invasive nature or potential false negativity of the endomyocardial biopsy, imaging methods represent as a major alternative to establish a clinical diagnosis. Among the imaging methods, the use of fluorine-18-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) which detects active inflammation in CS is becoming widespread. Recently, F-18 FDG PET has been identified as one of the new diagnostic criteria in CS, by the Heart Rhythm Society. For diagnosis, a combination of both myocardial perfusion and inflammation findings should be interpreted visually and/or semiquantitatively. Yet, the precision of diagnostic accuracy has been limited by lack of an adequate reference standard. This procedure guideline presents current literature defining the role of F-18 FDG PET in the diagnosis and management of CS along with technical details and recommendations about imaging protocol and interpretation. © 2020 Nuclear Medicine Seminars. All Rights Reserved.tr10.4274/NTS.GALENOS.2020.0015info:eu-repo/semantics/openAccessCardiac Sarcoidosis; F-18 Fdg Pet/Ct; InflammationFluorodeoxyglucose F 18; Article; Cardiac Sarcoidosis; Diagnostic Accuracy; Diagnostic Test Accuracy Study; Heart Muscle Perfusion; Human; Inflammation; Positron Emission Tomography-Computed Tomography; Practice Guideline; StandardArticle622112192-s2.0-85183311138N/A